Drug Trial Radar · NCT01453907
Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers
Last checked: Nov 20, 2026Latest source record: Nov 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
108
Actual
Start
Oct 2011
Primary completion
Jun 2012
Study completion Dec 2012
Sponsor
- Lead sponsor
- Elusys TherapeuticsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 18, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will determine the safety and PK of a single IV dose of ETI-204 in subjects 18 to 65 years of age. Three cohorts will be studied with subjects receiving ETI-204. This study will be randomized, double-blind and stratified by gender. Each cohort will contain 36 subjects (including at least four females), 30 who will receive ETI-204 and six who will receive placebo.
Conditions
- Anthrax
Interventions
ETI-204, "Anthim"Drug
intravenously, single dose
placeboDrug
intravenously, single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary ObjectiveTime frame: 71 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quintiles
Overland Park, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.